Back to search results

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Abroad (travel likely)RecruitingPHASE2

Conditions

Thyroid Cancer · Thyroid Carcinoma · Metastatic Thyroid Cancer · Follicular Thyroid Cancer · Unresectable Thyroid Gland Carcinoma · Papillary Thyroid Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Kenneth Burman, MD) · Kenneth.D.Burman@medstar.net · 202-262-2206
    Contact: Study coordinator (Kenneth Burman, MD)

  • Moffitt Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Sarimar Agosto Salgado, MD) · Sarimar.AgostoSalgado@moffitt.org · 813-745-0561
    Contact: Study coordinator (Sarimar Agosto Salgado, MD)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Lori J Wirth, MD) · lwirth@mgh.harvard.edu · 617-724-1134
    Contact: Study coordinator (Lori J. Wirth, MD)

  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Frank Worden, MD) · fworden@med.umich.edu · 734-36-5281
    Contact: Study coordinator (Frank Worden, MD)

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Theodore Laetsch, MD) · LAETSCHT@chop.edu · 267-425-5544
    Contact: Study coordinator (Theodore Laetsch, MD)

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Steven Sherman, MD) · sisherma@mdanderson.org · 713-792-2841
Study leads

  • Lori J. Wirth, MD

    Principal Investigator

    Massachusetts General Hospital

View source on ClinicalTrials.gov(opens in a new tab)